Who Paid My Doc
John Storheim
Anesthesiology Grand Junction, CO Doctor of Osteopathy
NPI 1699744367 CMS profile 553832
2635 N 7Th St, Grand Junction, CO 81501
General payments
$144,750
Research payments
$1,050
Ownership & investment interest
$0
Research they led as principal investigator
$58,903
Through program year 2025, John Storheim of Grand Junction, CO is reported in the CMS Open Payments database as having received $144,750 across 41 general payments and $1,050 in research payments paid to them. Separately, studies naming them as principal investigator received $58,903 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $45,000 | 12 | |
| 2024 | General | $42,000 | 12 | |
| 2023 | General | $42,000 | 12 | |
| 2023 | Research | $1,050 | 2 | |
| 2022 | General | $15,750 | 5 |
Beside peers
- John Storheim
- Anesthesiology median
- Middle half of Anesthesiology
- National median
In program year 2025, general payments to John Storheim were reported at $45,000. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.
Show as a table
| Year | John Storheim | Anesthesiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $72 | $23–$151 | $163 |
| 2020 | $0 | $36 | $17–$120 | $114 |
| 2021 | $0 | $49 | $21–$135 | $132 |
| 2022 | $15,750 | $52 | $22–$144 | $149 |
| 2023 | $42,000 | $53 | $23–$143 | $160 |
| 2024 | $42,000 | $55 | $25–$150 | $164 |
| 2025 | $45,000 | $58 | $26–$153 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 82 billing codesPaid by Medicare
$19,352,655
Medicare patients
1,243
Services billed
851,780
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 64% | |
| Arthritis | 54% | |
| Osteoporosis | 51% | |
| Ischemic heart disease | 34% | |
| Chronic kidney disease | 26% | |
| Depression | 26% | |
| Diabetes | 19% | |
| Heart failure | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc J9334 | Office | 20 | 110,880 | $2,865,915 |
| Injection, efgartigimod alfa-fcab, 2mg J9332 | Office | 11 | 85,600 | $2,161,682 |
| Injection, inclisiran, 1 mg J1306 | Office | 296 | 151,656 | $1,438,973 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg J1561 | Office | 31 | 29,828 | $1,148,148 |
| Injection, romosozumab-aqqg, 1 mg J3111 | Office | 97 | 113,400 | $969,309 |
| Injection, tildrakizumab, 1 mg J3245 | Office | 20 | 6,500 | $696,868 |
| Injection, denosumab, 1 mg J0897 | Office | 389 | 34,202 | $694,058 |
| Injection, vedolizumab, 1 mg J3380 | Office | 24 | 33,604 | $584,844 |
| Injection, ocrelizumab, 1 mg J2350 | Office | 13 | 12,600 | $563,311 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 | Office | 14 | 14,866 | $537,477 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
43 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Anesthesiology in Colorado
Related records
Anesthesiology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Anesthesiology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.